[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488342":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":61,"collaborators":43,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":43,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":43,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":47,"whyStopped":43,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Group","EXPERIMENTAL","Triple Antithrombotic Therapy: Aspirin (12 months) + Clopidogrel (12 months) + Rivaroxaban (3 months)",[13],"Drug: Aspirin + Clopidogrel + Rivaroxaban",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","OTHER","Dual Antiplatelet Therapy: Aspirin (12 months) + Clopidogrel (12 months)",[19],"Drug: Aspirin + Clopidogrel",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Aspirin + Clopidogrel + Rivaroxaban","Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily",[9],[27],"Triple Antithrombotic Therapy",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Aspirin + Clopidogrel","Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily",[15],[33],"Dual Antiplatelet Therapy",[35],{"name":36,"affiliation":37,"role":38},"Jinqing Yuan, MD","Chinese Academy of Medical Sciences, Fuwai Hospital","PRINCIPAL_INVESTIGATOR",[40],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","+86-10-68314466",null,"dr_jinqingyuan@sina.com",[46],{"facility":37,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Beijing","Beijing Municipality","100037","China","CN",{"type":54,"coordinates":55},"Point",[56,57],116.39723,39.9075,{"lat":57,"lon":56},[60],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},{"type":38,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"Jinqing Yuan","Deputy Director of Coronary Heart Disease Center, Director of Ward 1","100488342","phase-4-noac-therapy-guided-by-paris-risk-score-and-d-dimer-in-patients-with-acs-after-pci-100488342",false,"NCT05638867","NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI","A Randomized Controlled Clinical Trial of PARIS Coronary Thrombosis Risk Score Combined With D-dimer to Guide New Oral Anticoagulant Antithrombotic Therapy in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention","Inclusion Criteria:\n\n* Diagnosed with Acute Coronary Syndrome 1-7 days after initial symptom stabilization,\n* Aged 18-75 years old,\n* Elevated D-dimer levels (≥0.28 μg\u002Fml) on admission or PARIS coronary thrombosis risk score ≥ 3 points,\n* Received Percutaneous Coronary Intervention and not on non-oral anticoagulants,\n* Indicated for dual antiplatelet medication\n\nExclusion Criteria:\n\n* Platelet level below 90 x10\\^6\n* Hemoglobin level is less than 11g\u002FdL\n* History of severe bleeding\n* History of stroke\u002FTIA\n* Severe hepatic\u002Frenal insufficiency\n* Indicated for anticoagulation","ALL","18 Years","75 Years",{"count":75,"type":76},3944,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk. The main questions it aims to answer are:\n\n* Whether the intervention is effective in reducing ischemic events\n* Whether the intervention is safe from increasing bleeding events, especially severe or fatal ones\n\nParticipants will be randomized to receive standard DAPT therapy for the entire study duration or low-dose rivaroxaban+DAPT for 3 months, followed by standard DAPT for the rest of the study duration. Patients enrolled should complete 5 follow-ups in the form of clinic visit or telephone call.",[82,83,84],"Coronary Artery Disease","Percutaneous Coronary Intervention","Acute Coronary Syndrome",[86,87,88,84,83],"Novel Oral Anticoagulant","PARIS risk score","D-dimer","2026-08-09",{"date":91,"type":92},"2026-08-11","ACTUAL",{"date":94,"type":92},"2023-11-25",{"date":96,"type":76},"2027-01",{"name":5,"class":6},1]